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Abstract
Introduction: Excellent results regarding clinical efficacy 
and cost reduction are achieved by using certified repro-
cessed single-use medical devices (SUMDs). This explains 
why this practice is common in most hospitals across the 
USA and Germany. However, this is not a common practice 
at a national level and there are no reports regarding its use 
in Portugal. We present our experience using these methods 
at Centro Hospitalar de São João (CHSJ) in Porto. Objective: 
The aim of this study was to compare the clinical results and 
the financial impact of the use of 2 SUMDs, original and re-
processed, namely the linear suture machine GIA CovidienTM 
and Harmonic ACE® scissors. Method: A group of 733 pa-
tients operated in 2014 was evaluated. Of these patients, 316 
were operated on with reprocessed SUMDs and 417 with 
original SUMDs. Variables referring to the clinical and finan-
cial results were analyzed through clinical and management 
information provided by Unidade de Gestão Autónoma de 
Cirurgia. A comparison between groups was performed us-
ing the χ2 test and the Mann-Whitney test. Results: Indica-
tors related to clinical efficacy show that the use of these 
SUMDs, professionally reprocessed, did not represent any 
added risk in comparison to the use of original devices. Re-
garding costs, there is a very significant difference between 
the use of a new medical device and that of a reprocessed 
one. In the case of the Harmonic ACE® scissors and of the 
linear suture machine GIA CovidienTM, savings were up to 
50% per device. Conclusion: This study, the first in Portugal, 
confirms the economic advantages of reprocessing these 2 
devices. The financial benefit was obtained with mainte-
nance of the same clinical results as the ones achieved using 
original devices. These results are in line with the published 
literature, proving the validity of using SUMDs after profes-
sionally certified reprocessing.
© 2019 The Author(s). Published by S. Karger AG, Basel 
on behalf of Escola Nacional de Saúde Pública
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Resumo
Introdução: Os excelentes resultados da eficácia clínica e 
da redução de custos, obtidos com o reprocessamento 
certificado dos Dispositivos Médicos de Uso Único 
(DMUU) justificam que seja prática corrente na maior par-
te dos hospitais, nos Estados Unidos da América e na Ale-
manha. No entanto, a nível Nacional ainda não é prática 
comum, não existindo bibliografia sobre a experiência 
nacional. Apresentamos os resultados obtidos com esta 
prática no Centro Hospitalar de São João (CHSJ), Porto. 
Objetivo: Comparar os resultados clínicos e o impacto fi-
nanceiro da reutilização de dispositivos médicos de uso 
único, reprocessados profissionalmente. Foram utiliza-
dos dois dispositivos de “uso único,” a máquina de sutura 
linear GIA CovidienTM e a tesoura Harmonic ACE®. Méto-
do: Analisamos um grupo de 733 doentes operados em 
2014 que inclui todos os doentes operados no referido 
período e em que foram utilizados estes dispositivos. 
Destes doentes 316 foram operados com DMUU repro-
cessados, e 417 com DMUU originais. As variáveis referen-
tes aos resultados clínicos e financeiros foram analisadas 
através dos respetivos registos clínicos e da informação 
de gestão fornecida pela Unidade de Gestão Autónoma 
de Cirurgia. A comparação entre grupos foi realizada pela 
aplicação dos testes de Qui-quadrado e Mann-Whitney. 
Resultados: Os indicadores relativos à eficácia clínica, 
comprovaram que o uso destes DMUU reprocessados 
profissionalmente utilizados nas intervenções cirúrgicas 
não representou qualquer risco acrescido em compara-
ção com os dispositivos originais. Em termos financeiros, 
há uma diferença muito significativa entre a aquisição de 
um dispositivo médico novo ou reprocessado. A diferen-
ça no caso da tesoura Harmonic ACE® e na máquina de 
sutura linear GIA CovidienTM acarretou poupanças cerca 
de 50%. Conclusão: Este primeiro estudo, realizado em 
Portugal, confirma as vantagens económicas do repro-
cessamento destes dois dispositivos. O benefício finan-
ceiro foi obtido com manutenção da mesma qualidade 
clínica que se obteve com os dispositivos originais. Os re-
sultados obtidos estão em conformidade com os publica-
dos na literatura, o que confirma que a utilização de al-
guns dispositivos médicos de uso único após reproces-
samento profissional é um método eficiente.
© 2019 The Author(s). Published by S. Karger AG, Basel 
on behalf of Escola Nacional de Saúde Pública
Introduction
For many years, health-care units have been facing sig-
nificant challenges regarding the ideal management of fi-
nancial resources. New sustainability solutions cannot 
put at risk the safety of the patients, allowing profession-
als the use of appropriate resources to provide proper 
care. Within these boundaries, the use of certified profes-
sionally reprocessed single-use medical devices (SUMDs) 
is considered [1, 2]. 
In Portugal, SUMDs are defined according to the law 
decree number 145/2009 from the 17th of June (article 3, 
item r) as “(...) a device used for a single time on a single 
patient” [3]. Reprocessing is a certified procedure that al-
lows that some SUMDs can be used again after their first 
usage. European and national legislation [4–6] support 
this approach. This approach implies rigorous cleaning 
procedures, disinfection, and sterilization, as well as tests 
and the restoration of technical and functional safety of 
the used device [7, 8]. 
This practice was initiated in the USA around 20 years 
ago and in the last 15 years in Germany [1]. The excellent 
results regarding cost reduction and clinical efficiency 
promote it as an example of good clinical practice and 
reinforce that some SUMDs, after adequate professional 
handling, may be used again, especially in the areas of 
cardiology and electrophysiology, ophthalmology, en-
doscopy, and laparoscopy [8].
Since 2012, Centro Hospitalar de São João (CHSJ) has 
been using 2 reprocessed SUMDs (linear suture machine 
GIA CovidienTM and the Harmonic ACE® scissors), re-
processed by a certified reprocessor duly accredited [9]. 
Two studies evaluated the safety and performance of re-
processed Harmonic ACE® scissors as compared to new 
ones. In the first study, scenarios were developed in which 
the reprocessed device was subject to contamination 
(storage, transportation, and cleaning) followed by a 
2-year accelerated aging process. No signs of visible con-
tamination were detected, with insignificant levels of pro-
tein and hemoglobin [10]. In the second study, perfor-
mance was compared assessing in vivo dissection charac-
teristics and postcut shaft temperatures in Harmonic 
ACE® scissors and its counterpart [11]. In both studies, 
it was verified that the performance and safety of repro-
cessed Harmonic ACE® scissors are equivalent to the 
original [10, 11].
The objective of our study was to evaluate the clinical 
and financial consequences of the use of certified repro-
cessed SUMDs. 
de Sousa Martins et al.Port J Public Health 2018;36:150–156152
DOI: 10.1159/000496299
Materials and Methods
Information was provided by the Unidade Autónoma de 
Gestão de Cirurgia do CHSJ. Data collection was done using the 
management reports from the CHSJ in 2014 and the grouping of 
encrypted diagnosis-related groups (DRGs).
We selected all surgical interventions performed in 2014 in 
which Harmonic ACE® scissors curves (5 mm/36 cm C/rod) and 
the linear suture machine GIA CovidienTM with cut and anastomo-
sis (No. 55/60-3.8, No. 75/80-3.8, and No. 75/80-4.8) were used, 
either original or reprocessed devices. The hospital selected these 
2 devices due to original cost and/or large consumption number. 
The populations under study are described using their demo-
graphic characteristics. Clinical efficacy is described by data on 
duration of surgical intervention, postoperative infection inci-
dence, antibiotic consumption (using the daily dose defined 
[DDD]), reoperations, length of hospital stay, in-hospital mortal-
ity, and re-hospitalization rate (complications 30 days after surgi-
cal intervention). Cost analysis was based on the cost difference 
between the acquisition of unique SUMDs as compared to the 
costs of these SUMDs professionally reprocessed.
Statistical Analysis
A comparison between the groups regarding clinical effective-
ness was performed using the χ2 test to verify if there were signifi-
cant differences between categorical variables. The Mann-Whit-
ney test was used to analyze the significant differences between 
numerical variables. A p value of < 0.05 was considered statisti-
cally significant. For the cost analysis, the comparison between 
groups was based on the cost of purchasing SUMDs from the man-
ufacturer compared to the costs of the reprocessing of the same 
SUMDs. Acquisition of refills for the linear suture machine GIA 
CovidienTM was also considered in the analysis.
Sample
Surgical interventions were identified for each DRG in which 
SUMDs were used, regardless of those devices being original or 
reprocessed. Two groups were defined. Patients either operated on 
with original medical devices (nonreprocessed [NR] group) or 
with reprocessed medical devices (R group). A total of 733 surgical 
interventions were analyzed, during which 316 patients were treat-
ed with reprocessed SUMDs and 417 with nonreprocessed SUMDs.
The DRGs, referring to the surgical interventions analyzed, are 
shown in Table 1.
Results
Clinical Outcomes
The mean age in the R group was 56.7 ± 17.3 years and 
in the NR group 56.6 ± 16.7 years. In both groups, females 
were predominant (Table 2).
Table 1. Procedures performed by DRGs
DRGs R NR Total
148 Major procedures in the small intestine and/or large intestine, with CC 42 55 97
149 Major procedures in the small intestine and/or large intestine, without CC 21 49 70
154 Procedures in the esophagus, stomach, and/or duodenum, age >17 years, with CC 30 39 69
155 Procedures in the esophagus, stomach, and/or duodenum, age >17 years, without CC 29 40 69
288 Procedures in the stomach for obesity 56 69 125
293 Other procedures, by endocrine, nutritional, and/or metabolic diseases, in OR, without CC 40 34 74
359 Procedures in the uterus and/or its attachments for carcinoma in situ and/or nonmalignant disease, 
without CC
19 40 59
585 Major procedures in the stomach, esophagus, duodenum, small intestine, and/or large intestine, with 
CC
40 68 108
75 Major thoracic procedures 39 23 62
Total 316 417 733
R, reprocessed; NR, nonreprocessed; DRG, diagnosis-related group; CC, complications; OR, operating room.
Table 2. Demographic characteristics
R (n = 316) NR (n = 417) p
Mean age ± SD, years 56.7±17.3 56.6±16.7 0.996
Male, n (%) 132 (41.8) 166 (39.8) 0.592
Female, n (%) 184 (58.2) 251 (60.2) 0.592
R, reprocessed; NR, nonreprocessed.
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The postoperative infection rate was on average 12.9%, 
being 12.3% for the R group and 13.4% for the NR group. 
There was a wide range of differences in the rate of post-
operative infections in each DRG group, depending on 
the type of surgery and the severity of the preoperative 
condition. Still, there were no differences between the 2 
groups (p = 0.664).
Table 3 describes the consumption of antibiotics (as 
DDD), length of hospital stay, time of surgery, readmis-
sion rate, and in-hospital mortality. A comparison of the 
consumption of antibiotics (DDD) between the R and NR 
groups and for all DRG subgroups showed no significant 
differences (p = 0.319).
The duration of the surgical intervention was on aver-
age 2 h and 23 min (p = 0.161), and length of hospital stay 
was approximately 10 days in both groups (p = 0.881). 
Rehospitalization was required for 28 patients in the R 
group and for 33 patients in the NR group (p = 0.678).
Table 4. Cost difference between cases
List of medical devices R NR Savings
Harmonic ACE ®  scissors






Linear suture machine with cut and anastomosis GIA CovidienTM 


















R, reprocessed; NR, nonreprocessed. a Includes the purchase of 
2 original staple cartridges.
Table 3. Clinical outcomes
DRG SUMD Consumption of 
Antibiotics
Length of hospital stay Duration of surgical 
intervention
Re-hospitalization Mortality
DDD ± SD p days ± SD p hours ± SD p n (%) p n (%) p
75 NR 6.13±14.04 0.313 7.61±4.81 0.663 1.53±0.75 0.667 2 (8.70) 0.581 0 0.000
R 2.4±2.48 6.72±2.93 1.59±0.72 2 (5.13) 0
148 NR 3.21±5.53 0.113 11.4±9.78 0.083 2.28±1.21 0.664 6 (10.90) 0.258 0 0.044
R 4.55±8.34 13.55±11.14 2.22±1.25 8 (19.05) 3 (7.14)
149 NR 7.21±14.5 0.852 8.67±6.32 0.564 2.09±1.00 0.599 3 (6.81) 0.613 0 0.000
R 3.9±5.51 10.52±9.04 2.31±172 2 (9.54) 0
154 NR 3.29±8.04 0.193 11.41±10.25 0.079 3.52±1.68 0.348 5 (12.82) 0.419 0 0.000
R 3.55±5.72 12.2±7.26 3.39±2.11 6 (20.00) 0
155 NR 9.91±28.42 0.75 8.53±12.07 0.694 2.07±1.19 0.298 5 (12.50) 0.783 0 0.000
R 3.82±5.96 5.62±3.58 2.24±1.20 3 (10.34) 0
288 NR 4.68±13.4 0.453 8.65±12.9 0.463 2.07±0.61 0.879 2 (2.90) 0.677 0 0.000
R 3.8±8.19 6.52±3.26 2.08±0.60 1 (1.79) 0
293 NR 5.86±8.44 0.166 9.32±11.35 0.038 1.11±0.53 0.507 0 0.000 0 0.000
R 2.94±7.37 5.73±0.78 1.06±0.51 0 0
359 NR 7.72±26.64 0.714 6.93±13.68 0.022 2.12±0.75 0.764 0 0.000 0 0.000
R 4.99±7.06 2.84±0.6 2.04±1.12 0 0
585 NR 4.4±7.19 0.129 16.44±15.48 0.058 3.37±2.20 0.904 10 (14.70) 0.967 12 (17.64) 0.141
R 7.35±12.07 19.7±14.14 3.34±2.06 6 (15.00) 3 (7.50)
All DRGs NR 5.61±15.21 0.319 10.36±12.00 0.881 2.45±1.52 0.161 33 (7.91) 0.678 12 (2.88) 0.396
R 4.10±7.63 9.55±8.92 2.33±1.53 28 (8.86) 6 (1.90)
DRG, diagnosis-related groups; SUMD, single-use medical device; R, reprocessed; NR, nonreprocessed; SD, standard deviation; DDD, defined daily dose.
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Hospital mortality in the R group was 1.90%, resulting 
in 6 deaths, and it was 2.88% (12 deaths) in interventions 
in which new devices were used (NR group). Mortality 
was different in patients in DRGs 148 and 585. These in-
terventions were mostly life-saving procedures in ex-
tremely sick patients, with 11–36 patients having a sec-
ondary diagnosis, including cardiogenic shock and renal 
failure. The reasons for death were not related to the use 
of either reprocessed or nonreprocessed devices. There 
were no reoperations in either groups.
Cost Analysis
Data in Table 4 show the costs of purchasing new de-
vices as compared to the reprocessing costs of these 
SUMDs after use. Acquisition costs were obtained by the 
manufacturer company catalog that supplies the SUMDs 
to the CHSJ. Values for reprocessing were established be-
tween the CHSJ and the reprocessing company by proto-
col. The reprocessing costs of the devices include the eval-
uation and validation of the entire 7-step reprocessing 
cycle, from collection to delivery back to the hospital, 
with no additional costs.
The acquisition costs of the new Harmonic ACE® scis-
sors and those of reprocessed ones differed by 52% per 
device. In the case of the linear suture machine GIA Co-
vidienTM, the difference was less, due to the need to buy 
additional original staple cartridges. 
Table 5 shows the total of devices used as well as the 
costs with each of the options for the year 2014. Savings 
in Table 5 were calculated based on the difference be-
tween buying all SUMDs new without reprocessing and 
purchasing/reprocessing the SUMDs by the CHSJ. A to-
tal of 193 linear suturing machines GIA CovidienTM were 
reprocessed, saving EUR 14,623.61. These devices use 
staples that need to be originals and must be purchased 
separately. In each procedure, an average of 2 new car-
tridges was used. For this study, the value of EUR 7.5 
was used for each recharge, corresponding to an ex-
pense of EUR 2,895. Of the Harmonic ACE® scissors, 
285 were reprocessed, corresponding to savings of EUR 
75,932.55.
Discussion
Several authors have documented a cost reduction of 
around 50% due to the use of reprocessed SUMDs [12–
15]. Because of the strict requirements for a correct repro-
cessing, many hospitals use certified third-party outside 
bodies to reprocess their devices [16–19]. In addition to 
the economic advantages, reprocessing is now considered 
as one of the most efficient measures for hospitals to im-
mediately reduce some of their negative environmental 
impact [20, 21]. Approximately 10 million medical de-
vices have been reprocessed in the German market with 
strict quality standards for reprocessing approved by the 
national regulatory boards, and there were no complaints 
concerning this activity [16].
In our study, the groups submitted to surgical inter-
vention with reprocessed and nonreprocessed SUMDs 
were comparable with respect to their demographic 
characteristics. The incidence of infection was similar in 
both groups. We measured this incidence using the 
postoperative infection rate and an analysis of the con-
sumption of antibiotics, which is a more differentiated 
method of tracing the eventual occurrence of infectious 
complications, which would lead to an increase in the 
consumption of antibiotics. If this had happened, it 
might have been due to the use of the reprocessed de-
vices [10]. The duration of the surgical intervention and 
Table 5. Total cost with single-use medical devices (Harmonic ACE® scissors and linear suture machine GIA 
CovidienTM)
2014
linear suture machine GIA 
CovidienTM, n
expense Harmonic ACE® 
scissors, n
expense
NR 178 23,819.96 EUR 418 214,195.74 EUR
R 193 + recharge (386) 11,203.65 EUR 285 70,110.00 EUR
Savings – 14,623.61 EUR – 75,932.55 EUR
R, reprocessed; NR, nonreprocessed.
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the length of hospital stay were similar in both groups, 
which confirms the scientific evidence found interna-
tionally [11].
There were no significant differences between the use 
of new and reprocessed devices regarding the incidence 
of rehospitalization and hospital mortality. The analysis 
by DRG subgroups showed a difference in mortality in 
DRGs 148 and 585. Out of the 18 patients who died in 
these 2 groups, 6 were operated on using reprocessed de-
vices and the other 12 using original devices. It has to be 
emphasized that these DRGs refer to pathologies of the 
gastrointestinal system in patients who, at the time of sur-
gery, already suffered from established severe complica-
tions, such as sepsis, severe bleeding, pulmonary embo-
lism, and shock. The reason for death was not related to 
the use of the devices in any case. There was no need for 
reoperations in either group.
As a result, no increased risk was revealed with regard 
to the use of reprocessed SUMDs compared to the use of 
original SUMDs, and, therefore, reprocessed SUMDs do 
not compromise patient safety. Our experience shows 
that the concerns pronounced by several entities, which 
point out eventual risks associated with patient safety as 
an argument for not using reprocessed SUMDs, are not 
justified, and it confirms published data about the safety 
of using properly reprocessed SUMDs [16, 17, 22].
With regard to the economic analysis indicators, there 
is a huge difference between the cost of acquiring a new 
SUMD and a reprocessed device, and this difference in 
the case of the Harmonic ACE® scissors and the linear 
suture machine GIA CovidienTM comprises a saving 
around 50% per device, confirming the results obtained 
in international studies [15, 16, 23, 24]. This practice al-
lowed for a yearly saving of EUR 90,556.16 just for the 2 
devices.
Each medical device analyzed here can be reprocessed 
up to 2 times, which means that each new medical device 
purchased can be used 2 more times after professional 
treatment. To perform a fourth surgery, a new medical 
device needs to be purchased. A total of 596 new devices 
were purchased; 478 went through 1 reprocessing cycle, 
so by the year 2014 the stock of new devices was suffi-
cient. 
Our data are consistent with the fact that the certified 
reprocessing process requires a rigorous inspection, 
obeying demanding criteria and guidelines specific to 
each device. These stringent criteria allow the detection 
of any type of anomaly, which is not the case in original 
medical devices whose quality control is done by sam-
pling [19, 25, 26].
It is important to emphasize that not all SUMDs are 
reprocessable. Before they are accepted for clinical use, 
the methods of reprocessing, specific for each device, are 
validated and approved by the regulatory agencies, as 
was done with the devices our hospital had chosen to use 
[19].
Over the years, CHSJ has increased the use of repro-
cessed SUMDs. If this growth continues, it is expected 
that the optimum number of uses of these 2 devices can 
be reached. This approach allows a better use of re-
sources, leading to an improvement in hospital sustain-
ability.
Conclusion
Our study is the first analysis in Portugal of clinical and 
financial results obtained for patients undergoing surgi-
cal procedures using certified professionally reprocessed 
SUMDs (Harmonic ACE® scissors and linear suture ma-
chine). To assess clinical efficacy, a comparison was made 
with a similar group of patients undergoing surgical in-
tervention with original devices in the same time period. 
Clinical results of patients operated on with reprocessed 
devices were the same as those of patients in which origi-
nal medical devices were used.
Financially, the economic benefits of reprocessing are 
evident, contributing to fostering a culture of economic 
sustainability of hospitals by reducing costs while main-
taining quality of care. We conclude that certified repro-
cessing of SUMDs has proved to be a safe and effective 
process, leading to better hospital sustainability.
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